Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on KALIBRATE TECHNOLOGIES PLC. We currently have 17 research reports from 1 professional analysts.
|20Mar17 16:46||RNS||Holding(s) in Company|
|14Mar17 07:00||RNS||Interim Results|
|22Feb17 09:38||RNS||Holding(s) in Company|
|16Feb17 09:00||RNS||Notice of Results|
|31Jan17 09:19||RNS||Holding(s) in Company|
|27Jan17 15:17||RNS||Holding(s) in Company|
|24Jan17 07:00||RNS||Trading Update|
Frequency of research reports
Research reports on
KALIBRATE TECHNOLOGIES PLC
KALIBRATE TECHNOLOGIES PLC
N+1 Singer - Morning Song 14-03-2017
14 Mar 17
Advanced Medical Solutions (AMS LN) Prelims slightly ahead, still no deals | Brady (BRY LN) Investment will impact profits, but provide a platform for stronger growth | Burford Capital (BUR LN) Strong growth, many opportunities | First Derivatives (FDP LN) Collaboration agreement | Gresham Technologies (GHT LN) A milestone year | Gym Group (GYM LN) In line finals | Horizon Discovery Group (HZD LN) Agreement in pre-natal diagnostics | Kalibrate Technologies (KLBT LN) Near-term challenges, building long-term value | Stadium Group (SDM LN) Strong current trading; Strategic US investment | Zotefoams (ZTF LN) Currency tailwind underpins strong PBT growth; promising HPP progress
N+1 Singer - Kalibrate Technologies - Trading update – contract delays
24 Jan 17
Kalibrate issued a trading update indicating revenue and EBITDA for the current financial year (ending June 2017) are expected to be materially below expectations. Delays to signing of contracts and the commencement of certain backlog projects are the key reasons. The group had indicated last Sept that its continued growth is predicated on securing significant wins in Rest of World (India, Asia and Latin America), the timing of which is difficult to predict. The group has already taken action to reduce the cost base to protect profitability and cash (net cash stood at $3.1m, up from $2.4m in FY’16). We have put our forecasts under review, but expect the group to be profitable in the current year. Kalibrate has a strong market position and has significant opportunities for cross-selling within its customer base. So whilst there are near-term revenue challenges, we believe the group’s medium-term prospects, particularly with its continued investments in Rest of World, Merchandising and B2B Pricing, remain healthy.
N+1 Singer - Morning Song 24-01-2017
24 Jan 17
Harwood Wealth (HW LN) FY16 EBITDA 11% ahead, positive strategic progress | Horizon Discovery Group (HZD LN) Positive trading update, 2017e EBITDA guidance maintained | Kalibrate Technologies (KLBT LN) Trading update – contract delays | Marston’s (MARS LN) Decent start to the year | Murgitroyd Group (MUR LN) H1 trading behind budget | NCC Group (NCC LN) Rebuilding credibility from a sound base | Restore (RST LN) Positive conclusion to FY16 confirmed | Servelec Group (SERV LN) In line FY16 trading update | Xaar (XAR LN) Announcement of new FD
N+1 Singer - Morning Song 20-09-2016
20 Sep 16
Augean (AUG LN) Good H1 performance | Cello Group (CLL LN) Still moving in the right direction | Genus (GNS LN) Gene edited animals: exciting, but increases risk | Horizon Discovery Group (HZD LN) Interims and FY2016 guidance in line with expectations | Kalibrate Technologies (KLBT LN) In-line results; investing for growth | PuriCore (PURI LN) Disposal of Supermarket Retail | Swallowfield (SWL LN) Strong delivery in core business and owned brands
N+1 Singer - Kalibrate Technologies - In-line results; investing for growth
20 Sep 16
Kalibrate’s FY’16 revenues were slightly shy of our expectations but adjusted EBITDA was in line. SaaS transition continues, with annualised recurring revenues up 10%, but perpetual deals remain a feature (2 large deals in late Q4). The shape of the pipeline suggests there are some sizeable contracts to close, but the group is encouraged by developments and we make no changes to P&L forecasts. Given its track record and leadership in developed markets, Kalibrate is well-positioned in new markets that are deregulating. In addition, a broadening product set offers substantial cross-selling opportunities. Its medium-term prospects and competitive position remain strong.
FY outlook unchanged by H1 timing delays
15 Mar 16
Kalibrate delivered strong progress against its key metrics around core markets and new geographies, cross-selling, driving SaaS and recurring revenues and expanding product capability. However, the group’s interim performance was impacted by 3 pricing deals that slipped into H2, all of which have now been signed. Its FY outlook is unchanged, as are our forecasts, supported by a healthy pipeline. With more activity in the countries that have recently deregulated, more markets deregulating and a broader offering with Merchandising, we remain enthused as to its prospects and believe it is well positioned to capitalise on the growth opportunity.
Earnings upgrade following acquisition
17 Apr 17
Following the recent acquisition of Ingresso we upgrade our estimates by c10% in 2017. Ingresso owns and operates a software platform which enables sales through global third party distribution channels. This looks another smart acquisition by ACSO who continue to create a more efficient flow in the extremely fragmented leisure and ticketing industry. We increase our T/P to 2000p and upgrade to BUY.
N+1 Singer - Servelec Group - Calling the bottom
20 Apr 17
We are increasingly confident that Servelec’s travails are behind it and the business is returning to growth. Recent share price weakness looks unwarranted in this context and the valuation now looks compelling. Our forecasts are essentially unchanged, but we see medium term upside as the group’s markets improve. Servelec remains a key idea for 2017 and we reiterate our Buy recommendation and 325p Target Price.
Pickup in H2 organic growth as expected
20 Apr 17
Headline revenue growth of 19% reflects a full half contribution of ID Scan and a pickup in organic growth to 12% across the year driven by the excellent performance from the higher margin international services. The mix effects of this growth resulted in EBIT of £17m, 4% ahead of our forecasts, and a 1.1pp improvement in the operating margin.
Small Cap Breakfast
19 Apr 17
Global Ports Holding—Intention to float on Standard List. International cruise ports operator. Seeking $250m raise including $75m primary offer. Dorcaster—Schedule One Update. Admission now expected 3 May. RTO of Escape Hunt raising £14m at 135p Verditek— Intention to float on AIM. On Admission, the Company's subsidiaries will be involved in advanced solar photovoltaic, filtration and absorption technologies specialising in providing environmental services. Raising £3.5m. Admission in May. Eddie Stobart Logistics— Schedule 1. Admission expected 25 April but capital raising details TBC. ADES International Holding— Intends to join the Standard List in May raising up to $170m plus a vendor sale. Provider of offshore and onshore oil and gas drilling and production services in the Middle East and Africa. Admission expected in May. Tufton Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.
44% organic growth plus £7m of net cash
19 Apr 17
Many bank executives often complain about the reams of financial red-tape coming out of Brussels, London and New York. Not so Lombard Risk, which this morning delivered what can only be described as a ‘phenomenal’ set of results – reporting FY17 turnover, EBITDA and net cash all substantially above our estimates at £34.0m-£34.4m (vs ED at £31.8m), £2.4m-£2.8m (-£0.4m) and £7.0m (£1.4m) respectively.